SEGMENTED INFORMATION (Tables)

6 Months Ended

Jun. 30, 2024

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	MRNA Scientific			Chemrex Corporation			BGLC			Total
	Six months ended June 2024
REVENUE	$	8,661		$	4,347,754		$	-		$	4,356,415
COST OF REVENUE		(4,605	)		(3,698,059	)		-			(3,702,664	)
GROSS PROFIT		4,056			649,695			-			653,751
OTHER INCOME		76,058			855,894			-			931,952
OPERATING EXPENSES
General and administrative		(185,218	)		(696,763	)		(523,582	)		(1,405,563	)
(LOSS)/PROFIT FROM OPERATIONS		(105,104	)		808,826			(523,582	)		180,140
FINANCE COSTS		(4,595	)		(4,433	)		(113	)		(9,141	)
(LOSS)/PROFIT BEFORE TAX		(109,699	)		804,393			(523,695	)		170,999
Tax expense		-			(75,652	)		-			(75,652	)
NET (LOSS)/PROFIT	$	(109,699	)	$	728,741		$	(523,695	)	$	95,347

	MRNA Scientific			Chemrex Corporation			BGLC			Total
				Six months ended June 30, 2023
REVENUE	$	11,932		$	4,932,121		$	-		$	4,944,053
COST OF REVENUE		(7,548	)		(4,227,894	)		-			(4,235,442	)
GROSS PROFIT		4,384			704,227			-			708,611
OTHER INCOME		2,165			310,343			-			312,508
OPERATING EXPENSES
General and administrative		(98,720	)		(1,025,896	)		(219,333	)		(1,343,949	)
LOSS FROM OPERATIONS		(92,171	)		(11,326	)		(219,333	)		(322,830	)
FINANCE COSTS		(1,275	)		(4,212	)		-			(5,487	)
LOSS BEFORE TAX		(93,446	)		(15,538	)		(219,333	)		(328,317	)
Tax expense		-			-			-			-
NET LOSS	$	(93,446	)	$	(15,538	)	$	(219,333	)	$	(328,317	)

	As of June 30, 2024 and December 31, 2023
	Total Assets				Total Liabilities
	2024		2023		2024		2023
BGLC & MRNA Scientific	$	4,380,021		4,723,449	$	616,300	$	260,119
Chemrex Corporation		6,759,706		6,676,344		977,673		1,481,822
TOTAL		11,139,727		11,399,793		1,593,973		1,741,941